Clinical Scorecard: Effectiveness and Safety of Drug Therapies for Restless Legs Syndrome in Patients Undergoing Hemodialysis: A Systematic Review and Meta-Analysis

At a Glance

Key Highlights

• Pharmacologic therapy significantly improved IRLS scores, sleep quality, and quality of life.
• Gabapentinoids showed the largest symptom reductions among treatments.
• Dopaminergic agents had higher adverse event risks, particularly nausea and hypotension.
• Iron therapy provided moderate benefits with good tolerability.
• No TCM pharmacologic treatments could be quantitatively evaluated due to lack of standardized studies.

Guideline-Based Recommendations

Diagnosis

• RLS should be assessed in hemodialysis patients due to its high prevalence and impact on quality of life.

Management

• Gabapentinoids are recommended for managing RLS symptoms in hemodialysis patients.
• Dopaminergic agents can be used but with caution due to potential adverse effects.

Monitoring & Follow-up

• Monitor for adverse events, especially with dopaminergic agents.

Risks

• Increased risk of adverse events with dopaminergic agents, including augmentation and low blood pressure.

Patient & Prescribing Data

Adults on maintenance hemodialysis with Restless Legs Syndrome.

Gabapentinoids are effective but should be administered carefully due to sedation risks.

Clinical Best Practices

• Individualize treatment approaches to balance efficacy and safety.
• Consider iron supplementation in patients with low iron stores.

Related Resources & Content

• Systematic Review and Meta-Analysis